AR112755A1 - Proteína de fusión a una enzima terapéutica y su uso - Google Patents

Proteína de fusión a una enzima terapéutica y su uso

Info

Publication number
AR112755A1
AR112755A1 ARP180101915A ARP180101915A AR112755A1 AR 112755 A1 AR112755 A1 AR 112755A1 AR P180101915 A ARP180101915 A AR P180101915A AR P180101915 A ARP180101915 A AR P180101915A AR 112755 A1 AR112755 A1 AR 112755A1
Authority
AR
Argentina
Prior art keywords
fusion protein
enzyme
acid
sulfatase
therapeutic enzyme
Prior art date
Application number
ARP180101915A
Other languages
English (en)
Inventor
Sung Youb Jung
In Young Choi
Jin Young Kim
Yong Ho Heo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR112755A1 publication Critical patent/AR112755A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06012—N-Acetylgalactosamine-4-sulfatase (3.1.6.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se refiere a una proteína de fusión entre una enzima terapéutica y una región Fc de la inmunoglobulina, su método, y una composición que comprende la proteína de fusión. Reivindicación 2: La proteína de fusión a una enzima de la reivindicación 1, en donde la enzima terapéutica se selecciona del grupo que consiste en b-glucosidasa, a-galactosidasa, b-galactosidasa, iduronidasa, iduronato-2-sulfatasa, galactosa-6-sulfatasa, a-glucosidasa ácida, ceramidasa ácida, esfingomielinasa ácida, galactocerebrosidasa, arilsulfatasa A, B, b-hexosaminidasa A, B, heparina N-sulfatasa, a-D-manosidasa, b-glucuronidasa, N-acetilgalactosamina-6 sulfatasa, lipasa ácido lisosómica, a-N-acetil-glucosaminidasa, glucocerebrosidasa, butirilcolinesterasa, quitinasa, glutamato decarboxilasa, imiglucerasa, lipasa, uricasa, factor activador de plaquetas, acetilhidrolasa, endopeptidasa neutra y mieloperoxidasa. Reivindicación 3: La proteína de fusión a una enzima de la reivindicación 1, en donde una enzima terapéutica y una región Fc de la inmunoglobulina se fusionan mediante un conector peptídico.
ARP180101915A 2017-07-07 2018-07-10 Proteína de fusión a una enzima terapéutica y su uso AR112755A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20170086594 2017-07-07

Publications (1)

Publication Number Publication Date
AR112755A1 true AR112755A1 (es) 2019-12-11

Family

ID=64950229

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101915A AR112755A1 (es) 2017-07-07 2018-07-10 Proteína de fusión a una enzima terapéutica y su uso

Country Status (17)

Country Link
US (1) US20200157172A1 (es)
EP (1) EP3650539A4 (es)
JP (2) JP2020530283A (es)
KR (2) KR102413686B1 (es)
CN (1) CN111094559A (es)
AR (1) AR112755A1 (es)
AU (1) AU2018295994A1 (es)
BR (1) BR112020000273A2 (es)
CA (1) CA3069119A1 (es)
EA (1) EA202090084A1 (es)
IL (1) IL271837B2 (es)
MX (1) MX2020000037A (es)
PH (1) PH12020500054A1 (es)
SG (1) SG11202000115SA (es)
TW (1) TWI832818B (es)
WO (1) WO2019009684A2 (es)
ZA (1) ZA202000595B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200058510A (ko) 2017-10-02 2020-05-27 데날리 테라퓨틱스 인크. 효소 대체 요법 효소를 포함하는 융합 단백질
US20210009984A1 (en) * 2017-12-22 2021-01-14 Hanmi Pharm. Co., Ltd. Therapeutic enzyme fusion protein having a novel structure and use thereof
IL302029A (en) 2020-10-14 2023-06-01 Denali Therapeutics Inc Fusion proteins containing sulfoglucosamine sulfohydrolase enzymes and methods thereof
EP4245311A1 (en) * 2020-11-13 2023-09-20 Hanmi Pharm. Co., Ltd. Use of therapeutic enzyme fusion protein for preventing and treating kidney disease caused or accompanied by fabry's disease
CA3196264A1 (en) * 2020-11-13 2022-05-19 Jin Young Kim Use of therapeutic enzyme fusion protein in prevention and treatment of neuropathy caused by or accompanied by farbry disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0136514B1 (ko) * 1994-12-23 1998-07-01 양승택 공통선 신호장치의 속도정합장치
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
MXPA03006294A (es) * 2001-01-18 2003-09-16 Merck Patent Gmbh Proteinas de fusion disfuncionales con actividad glucocerebrosidasa.
KR100900176B1 (ko) * 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
DK2270050T3 (da) * 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
AU2008206923A1 (en) * 2007-01-17 2008-07-24 Merck Serono S.A. Process for the purification of Fc-containing proteins
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
EP3783017A1 (en) * 2013-04-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Fc region variant
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
US20160193295A1 (en) * 2013-07-31 2016-07-07 Amgen Inc. Stabilization of fc-containing polypeptides
AU2014342182B2 (en) * 2013-10-30 2020-05-14 Eberhard Karls Universitat Tubingen Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta TCR -binding polypeptide
WO2017062619A2 (en) * 2015-10-08 2017-04-13 Macrogenics, Inc. Combination therapy for the treatment of cancer
PL3386534T3 (pl) * 2015-12-08 2021-03-08 Regeneron Pharmaceuticals, Inc. Kompozycje i sposoby internalizacji enzymów
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas

Also Published As

Publication number Publication date
EP3650539A2 (en) 2020-05-13
IL271837B1 (en) 2023-09-01
KR20220098092A (ko) 2022-07-11
KR102556411B1 (ko) 2023-07-18
ZA202000595B (en) 2021-04-28
JP2020530283A (ja) 2020-10-22
CA3069119A1 (en) 2019-01-10
KR102413686B1 (ko) 2022-06-28
IL271837A (en) 2020-02-27
MX2020000037A (es) 2020-08-06
IL271837B2 (en) 2024-01-01
TWI832818B (zh) 2024-02-21
CN111094559A (zh) 2020-05-01
KR20190005803A (ko) 2019-01-16
TW201906872A (zh) 2019-02-16
AU2018295994A1 (en) 2020-02-06
WO2019009684A3 (ko) 2019-03-28
US20200157172A1 (en) 2020-05-21
SG11202000115SA (en) 2020-02-27
BR112020000273A2 (pt) 2020-07-14
EA202090084A1 (ru) 2020-06-19
EP3650539A4 (en) 2021-08-18
WO2019009684A2 (ko) 2019-01-10
PH12020500054A1 (en) 2020-09-21
JP2023085445A (ja) 2023-06-20

Similar Documents

Publication Publication Date Title
AR112755A1 (es) Proteína de fusión a una enzima terapéutica y su uso
CO2019014682A2 (es) Composiciones y métodos para enzimas de internalización
HRP20180291T1 (hr) Postupci za sparivanje ciljajućeg peptida na rekombinantne lizosomalne enzime za poboljšano liječenje lizosomskih bolesti nakupljanja
Ferreira et al. Purification and characterization of a β-mannanase from Trichoderma harzianum strain T4
PH12020550510A1 (en) Fusion proteins comprising enzyme replacement therapy enzymes
Andberg et al. Swollenin from Trichoderma reesei exhibits hydrolytic activity against cellulosic substrates with features of both endoglucanases and cellobiohydrolases
ES2612512T3 (es) Procedimiento para tratar el material celulósico y enzimas CBHII/CEL6A útiles en el mismo
RU2011102781A (ru) ПРИМЕНЕНИЕ Hsp70 В КАЧЕСТВЕ РЕГУЛЯТОРА ФЕРМЕНТАТИВНОЙ АКТИВНОСТИ
MX2014006594A (es) Compuestos de enzimas lisosomales apuntados.
AR101956A1 (es) Composiciones que comprenden células recombinantes de bacillus y otro agente de control biológico
Vasina et al. Extracellular proteins of Trametes hirsuta s t. 072 induced by copper ions and a lignocellulose substrate
MX367024B (es) Proteinas de fusion de enzima lisosomal terapeutica objetivo y usos de las mismas.
JP2019506164A5 (es)
WO2010059424A3 (en) Methods and compositions for degrading cellulosic material
ATE481883T1 (de) Milchfreie milchersatzprodukte
WO2012125937A3 (en) Glycosyl hydrolase enzymes and uses thereof for biomass hydrolysis
Valaškova et al. Degradation of cellulose and hemicelluloses by the brown rot fungus Piptoporus betulinus–production of extracellular enzymes and characterization of the major cellulases
JP2008521906A5 (es)
IN2012DN01492A (es)
IN2013MN00618A (es)
WO2014018368A3 (en) Methods for increasing enzymatic hydrolysis of cellulosic material
AR101958A1 (es) Composiciones que comprenden células recombinantes de bacillus y un fungicida
PE20171798A1 (es) Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada
Coughlan Mechanisms of cellulose degradation by fungi and bacteria
NZ765453A (en) Therapeutic enzyme fusion protein having novel structure and use thereof